Biosimilar Antibodies

Lanerkitug is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets CCR8. For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control. This specificity makes Lanerkitug suitable for research focused on the role of CCR8 in immune responses and potential therapeutic applications.

Domagrozumab is a humanized monoclonal antibody that targets myostatin with a dissociation constant (K_D) of 2.6 pM, indicating high affinity binding. By inhibiting myostatin, a negative regulator of muscle growth, Domagrozumab promotes anabolic activity in muscle tissues. This antibody is primarily utilized in research focused on Duchenne Muscular Dystrophy (DMD), providing a valuable tool for studying the pathology and potential therapeutic interventions for this condition.

Porgaviximab is a monoclonal antibody designed for the study of Ebola virus infections. This antibody targets specific antigens associated with the Ebola virus, making it a valuable tool for researchers investigating the pathogenesis, immune response, and potential therapeutic interventions for this deadly virus. Porgaviximab is suitable for use in a variety of experimental setups, including viral neutralization assays and immunohistochemistry studies.

Pradusinstobart is a human IgG4 κ monoclonal antibody targeting PDCD1 (Programmed Cell Death Protein 1). For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody that specifically targets protein tyrosine kinase 7 (PTK7). This antibody is produced using a Chinese Hamster Ovary (CHO) cell expression system, ensuring high fidelity and stability in the recombinant product. Cofetuzumab is designed for use in research applications focusing on the role of PTK7 in cancer pathogenesis and other related signaling pathways.

Fianlimab (REGN3767) is a human monoclonal antibody designed to specifically bind to the lymphocyte-activation gene 3 (LAG-3) immune checkpoint receptor expressed on T cells. This interaction inhibits the LAG-3 pathway, thereby enhancing T cell function and exhibiting potent anti-tumor activity. Fianlimab is utilized in oncological research to investigate immune checkpoint blockade as a strategy for cancer immunotherapy.

The Anti-TMEFF2 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the TMEFF2 protein. This antibody consists of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Garadacimab (CSL312) represents a pioneering advancement as a fully human IgG4 monoclonal antibody that specifically targets activated factor XII (FXIIa). This unique specificity renders it a valuable tool for investigating the pathophysiology and potential therapeutic interventions for hereditary angioedema.

Vecantoxatug is a humanized monoclonal antibody designed to target the Clostridium tetani toxin (TeNT, neurotoxin). By specifically binding to this toxin, Vecantoxatug inhibits its interaction with cellular receptors, effectively neutralizing its toxic effects. This antibody is particularly valuable for research focused on tetanus, offering potential insights into toxin mechanism and therapeutic interventions.

Ustekinumab is a human monoclonal antibody of the IgG1κ subclass that targets interleukin-12 (IL-12) and interleukin-23 (IL-23). This biologic is engineered to bind specifically to the p40 protein subunit shared by these cytokines, thereby inhibiting their interaction with the IL-12Rβ1 receptor and modulating immune responses involved in inflammatory pathways. Ustekinumab is utilized primarily in the study of immune-mediated disorders and has applications in the research of diseases such as psoriasis, Crohn’s disease, and other chronic inflammatory conditions.

Begelomab (SAND-26) is a murine IgG2b monoclonal antibody specifically targeting DPP-4/CD26. This antibody is utilized in research focused on severe refractory idiopathic inflammatory myopathy, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for this condition.

IMAB027 (ASP1650) is a monoclonal antibody specifically targeting CLDN6 (Claudin 6), a tight junction membrane protein. CLDN6 is aberrantly expressed in a range of human cancers, particularly in ovarian cancers. This antibody has demonstrated potent anti-tumor activity and can induce apoptosis in CLDN6-positive ovarian and testicular cancer cell lines. IMAB027 is utilized primarily in research focused on the pathological roles of CLDN6 in cancer and the therapeutic potential of targeting this protein in oncology.

Pepinemab (VX 15/2503) is a human monoclonal antibody designed to target and neutralize SEMA4D (Signaling Protein 4D), also recognized as CD100. SEMA4D is a critical regulator of neuronal development and is implicated in a range of cellular processes. By inhibiting the activity of SEMA4D, Pepinemab serves as a valuable tool for the investigation of neurodegenerative disorders, including Alzheimer's disease. This antibody is specifically engineered for research applications focused on elucidating the role of SEMA4D in disease pathogenesis and cellular function.

Amrecibart is a human IgG4 κ monoclonal antibody targeting coagulation factor XI. For optimal experimental control, it is recommended to use Human IgG4 kappa as an isotype control.

Tarcocimab (OG1953) is a humanized monoclonal antibody of the IgG1 subtype, specifically targeting VEGFA. This antibody is utilized in research focusing on retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD), offering a valuable tool for investigating the pathological mechanisms and potential therapeutic interventions for these ocular conditions.

Davutamig (REGN-5093) is a human IgG4-kappa monoclonal bispecific antibody designed to target two distinct, non-overlapping epitopes on the MET receptor. This antibody functions as an antineoplastic agent, primarily utilized in cancer research and therapy. Its unique bispecific nature allows for enhanced specificity and efficacy in targeting the MET receptor, a critical player in the pathology of various cancers.

Plutavimab is a human IgG1-κ monoclonal antibody specifically designed to target the receptor-binding domain (RBD) of the Spike (S) glycoprotein of SARS-CoV-2. This antibody binds with high specificity and affinity, potentially neutralizing the virus by preventing its entry into host cells. Plutavimab is suitable for research applications focused on the study of viral entry mechanisms, virus-host interactions, and the development of therapeutic strategies against SARS-CoV-2.

Enuzovimab (HFB-30132A) is a monoclonal antibody specifically developed to target the SARS-CoV-2 Omicron variant. It exhibits high-affinity binding to the spike (S) protein of the virus, offering potential utility in therapeutic interventions against this strain.

The Anti-Siglec-15/CD33L3 Antibody is derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets Siglec-15, also known as CD33L3, a sialic acid-binding Ig-like lectin involved in immune regulation. Comprising a human IgG1 heavy chain and a human lambda light chain, this antibody has a predicted molecular weight of 146.02 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This product is essential for research focusing on the role of Siglec-15 in immune responses and its potential implications in therapeutic interventions.

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody engineered to selectively bind and neutralize interleukin-17A (IL-17A) with a dissociation constant (K_D) of less than 3 pM. This antibody effectively inhibits the interaction of IL-17A with its receptor, IL-17RA, without interacting with other members of the IL-17 cytokine family. Ixekizumab is primarily utilized in research focused on the pathophysiology and treatment of moderate-to-severe plaque psoriasis.

Daxdilimab is a monoclonal antibody that targets ILT7, a cell surface molecule uniquely expressed on plasmacytoid dendritic cells (pDCs). This antibody has been specifically developed for research purposes, particularly to investigate its therapeutic potential in managing acute lung injury (ALI) associated with COVID-19 infection. Daxdilimab offers a promising tool for elucidating the role of pDCs in viral infections and inflammatory responses.

Rivabazumab pegol is a pegylated Fab monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa. This antibody is specifically designed for the investigation of chronic infections caused by Pseudomonas aeruginosa, offering a valuable tool for research in microbial pathogenesis and host-pathogen interactions during the persistent phases of this infection. Rivabazumab pegol's unique structure and specificity make it ideal for studies focused on the development and evaluation of therapeutic strategies against this challenging bacterial pathogen.

Ntx1088 is a first-in-class, potent monoclonal antibody that targets the poliovirus receptor, also known as CD155. This antibody has demonstrated potential therapeutic applications in the treatment of patients with locally advanced and metastatic solid tumors. Its specific interaction with CD155 makes it a valuable tool for research and potential clinical use in oncology.

Ginisortamab (UCB6114) is a fully human IgG4P monoclonal antibody targeting Gremlin-1. It demonstrates potent inhibitory activity with mean IC50 values of 8.2 nM and 9 nM against human and mouse Gremlin-1, respectively. By antagonizing Gremlin-1, Ginisortamab effectively disrupts the BMP signaling pathways, which are crucial in various biological processes including tissue growth and repair. This antibody holds significant potential for use in research focused on gastrointestinal (GI) tumors, providing a valuable tool for elucidating the role of Gremlin-1 in cancer pathogenesis and therapy.

Bezetabart is a human IgG1 κ monoclonal antibody targeting CD74. For accurate experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Lofacimig is a bispecific antibody designed as a VH-VH-G1(h-CH2-CH3) dimer, specifically targeting FXI and PTA. This configuration enhances its specificity and efficacy in engaging these particular antigens, making it a valuable tool for research into coagulation and anticoagulation pathways.

ANX005 is a recombinant antibody specifically targeting C1q, the initiating molecule of the classical complement cascade. By inhibiting C1q, ANX005 is instrumental in the study of its role in autoimmune and neurodegenerative diseases. This antibody serves as a crucial tool for researchers investigating the mechanisms of immune response and disease progression in these conditions.

Anti-SLAMF7 / CS1 (PDL241) is a humanized monoclonal antibody specifically targeting CD319. This antibody is recognized for its potential as a therapeutic agent in the treatment of rheumatoid arthritis, leveraging its ability to modulate immune responses associated with the disease.

Ocankitug is a humanized IgG1κ monoclonal antibody specifically targeting thymic stromal lymphopoietin (TSLP). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody designed to neutralize proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR), Frovocimab facilitates the normal proteolytic processing of PCSK9 without disrupting its binding, thereby maintaining cholesterol homeostasis. This antibody is pivotal for research focused on lipid metabolism and cardiovascular diseases, offering potential insights into the regulation of cholesterol levels and the mechanisms of atherosclerosis.

Retifanlimab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, designed to modulate immune responses in tumor microenvironments. This antibody is particularly utilized in the study of gastroesophageal adenocarcinoma (GEA), providing a valuable tool for researchers investigating the therapeutic potential of PD-1 inhibition in this cancer type.

Oportuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target EpCAM (epithelial cell adhesion molecule), also known as TROP1 or CD326. This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, exhibiting a predicted molecular weight of approximately 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Verekitug is a human IgG1 κ monoclonal antibody targeting CRLF2. For optimal experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

Rimteravimab (XVR011) is a bivalent VHH-Fc antibody engineered for potent neutralization of SARS-CoV-2. This antibody exhibits broad coverage and high stability, and features silenced Fc effector functions, making it highly effective against the disease caused by SARS-CoV-2. Its design and functionality make it an essential tool for research into COVID-19 therapies and mechanisms of viral neutralization.

Ziltivekimab (COR-001) is a humanized monoclonal antibody designed to target interleukin-6 (IL-6), a cytokine known to play a critical role in systemic inflammation. This antibody has demonstrated efficacy in lowering serum C-reactive protein (CRP) levels, indicating its potent anti-inflammatory properties. Ziltivekimab is primarily utilized in research focused on chronic systemic inflammation, particularly in conditions such as chronic kidney disease (CKD) and cardiovascular diseases, including atherosclerosis. Its specific interaction with IL-6 makes it a valuable tool for studies exploring the pathophysiology and potential therapeutic interventions for these diseases.

Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody engineered to bind with high affinity to the catalytic structural domain of Factor XI (FXI). This interaction effectively locks FXI in its zymogen conformation, inhibiting its activation by Factor XIIa (FXIIa) or thrombin. Due to its specific mechanism of action, Abelacimab is an excellent tool for research into thromboembolic diseases, providing insights into the regulation of coagulation pathways and the development of antithrombotic therapies.

Denrakibart is a human monoclonal antibody of the IgG2κ subtype that specifically targets CCL17. For experimental control purposes, it is recommended to use Human IgG2 kappa as the isotype control.

Namilumab (AMG203) is a human IgG1 monoclonal antibody designed to bind with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), effectively neutralizing its activity. This antibody is primarily utilized in research focused on understanding and treating rheumatoid arthritis, providing a valuable tool for investigating the role of GM-CSF in inflammatory processes.

Melrilimab (GSK 3772847) is a monoclonal antibody of the IgG2-kappa subclass that targets IL1RL1, also known as ST2, IL33R, DER4, and FIT-1. This antibody is specifically designed for the investigation of its role in asthma pathogenesis and potential therapeutic applications.

Drotokibart is a humanized IgG4κ monoclonal antibody that specifically targets the IL4RA protein. For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This specificity and control recommendation ensure precise and reliable results in research applications focusing on the IL4RA pathway.

Reozalimab is a bispecific antibody engineered to target both PD-1 and PD-L1. This unique formulation enhances the immune response against tumor cells by facilitating antibody-dependent cell-mediated cytotoxicity (ADCC). It is primarily utilized in oncological research to investigate immune checkpoint blockade therapies.

Romilkimab (SAR156597) is a chimeric humanized immunoglobulin antibody engineered to specifically target both interleukin-4 (IL-4) and interleukin-13 (IL-13). This dual specificity allows for potential therapeutic applications in treating diseases characterized by overactive IL-4 and IL-13 pathways, such as certain inflammatory and autoimmune disorders.

Apitegromab (SRK-015) is a monoclonal antibody targeting promyostatin. This biologic is specifically designed for the investigation of neuromuscular disorders, including spinal muscular atrophy. Apitegromab's mechanism involves modulating the activity of promyostatin, a key regulator in muscle development and growth, making it a valuable tool in research focused on muscle pathology and therapeutic development.

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal antibody targeting PD-L1 within the PD-1/PD-L1 pathway. Demonstrating significant antitumor activity, this antibody is particularly effective in treating solid tumors, such as extensive-stage small-cell lung cancer (SCLC). Adebrelimab's mechanism of action involves modulating the immune response by inhibiting the PD-1/PD-L1 interaction, thereby enhancing the body's antitumor immune activity. This product is pivotal for research focused on immune checkpoint pathways and cancer immunotherapy.

Birtamimab (NEOD001) is an investigational monoclonal antibody designed to specifically and selectively target and clear amyloid deposits. This antibody is primarily utilized in research focused on light chain amyloidosis, providing a targeted approach to study the pathological mechanisms and potential therapeutic interventions for this condition.

Landogrozumab (LY2495655) is a humanized monoclonal antibody targeting myostatin, a protein known to inhibit muscle growth. By neutralizing myostatin, Landogrozumab has been shown to enhance muscle volume, hand grip strength, and overall muscle function. This antibody is primarily utilized in research focused on muscle wasting diseases, providing a valuable tool for investigating potential therapeutic interventions for conditions characterized by muscle degeneration and loss.

Gontivimab (ALX-0171; VR-465) is a potent nanobody targeting the respiratory syncytial virus (RSV) prefusion F protein, exhibiting a dissociation constant (K_D) of 0.113 nM. This high-affinity binding is indicative of its robust antiviral properties. Gontivimab has demonstrated efficacy in reducing viral load in both nasal and pulmonary tissues, highlighting its potential for therapeutic applications in RSV infections.

Enristomig is a monoclonal antibody that targets TNFRSF9 and CD274, designed for precision in immunotherapy research. This antibody binds specifically to TNFRSF9, also known as CD137, and CD274, known as PD-L1, playing a crucial role in modulating immune responses. It is utilized extensively in studies focusing on cancer immunotherapy, autoimmune diseases, and immune checkpoint regulation.

Anatumomab mafenatox (ABR-214936) is a 73 kDa recombinant protein engineered to target the tumor-associated antigen 5T4, commonly expressed in various malignancies. This biologic agent is a fusion of a modified form of staphylococcal enterotoxin A (SEA) and a murine Fab fragment, designed for precise recognition and binding to the 5T4 antigen. Commonly reported adverse effects associated with Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness, which should be considered in therapeutic settings. This product is pivotal for research focused on the characterization and treatment of cancers expressing the 5T4 antigen.